An Open-label, Single Arm Study to Evaluate the Pharmacokinetics of a Single Dose of Intravenous Difelikefalin in Adolescents Aged 12 to 17 Years on Haemodialysis
Latest Information Update: 12 Mar 2024
At a glance
- Drugs Difelikefalin (Primary)
- Indications Renal failure
- Focus Pharmacokinetics
- Sponsors Vifor Fresenius Medical Care Renal Pharma
- 08 Mar 2024 This study has been discontinued in Italy, according to European Clinical Trials Database record.
- 27 Oct 2021 New trial record